GSK has yet to convince the market that it can avoid slipping off the patent cliff. Britain’s second biggest pharmaceuticals group is suspected of not investing enough in new treatments.
A strong debut from Arexvy, its breakthrough respiratory vaccine, might help to dispel the notion that the group is not doing enough to refill the hopper. The vaccine was launched in the United States in May and has been rolled out to 1.4 million adults above the age of 60.
Sales of £709 million for the new vaccine in the third quarter were ahead of expectations and provided a reason for another upgrade to group organic sales guidance. It expects sales growth of 12 per cent to 13 per cent this year, ex-Covid treatments, up
